Arrhythmias & electrophysiology
Effectiveness of the risk stratification proposed by the 2022 European Heart Rhythm Association Expert Consensus statement on arrhythmic mitral valve prolapse
Authors' conclusion
More than half of MVP patients referred for CMR met the AMVP diagnostic criteria. Despite low long-term event rates, in 70% of patients with AMVP the implantation of an ICD may be reasonable.
Study context
- Population
- Consecutive patients with mitral valve prolapse without alternative arrhythmic substrates, with CMR99 (58.6%) Arrhythmic MVP (AMVP)
- Participants
- 169 patients
- Outcome
- Composite of:
- SCD
- Ventricular tachycardia (VT)
- Inducible VT
- Appropriate ICD shocks
- Follow-up
- Median 8.0 years (IQR 5.0-15.6)
Methodological detailssingle-centre, consecutive patients
- Single-centre
- Consecutive patients
Main finding
As reported in the abstract
Composite arrhythmic end point incidence rate
Incidence rate, composite arrhythmic end point
0.3%/year
95% CI 0.1–0.8
Observational data: associations, not effects.
Further findings
Predictors of AMVP (multivariate logistic regression)
- Late gadolinium enhancement: OR
- 2.82 (95% CI 1.45-5.50)
- Mitral annular disjunction: OR
- 1.98 (95% CI 1.02-3.86)
- Only predictors of AMVP
EHRA risk stratification in AMVP
- Secondary prevention implantable cardioverter-defibrillator (ICD) indication
- 5 (5.1%)
- ICD implantation may be reasonable
- 69 (69.7%)
AMVP prevalence
- Classified as AMVP
- 99 (58.6%)
Original publication
Effectiveness of the risk stratification proposed by the 2022 European Heart Rhythm Association Expert Consensus statement on arrhythmic mitral valve prolapse. Am Heart J. Published 16 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →